Birthplace and Date:	Berlin, Germany, May 7, 1971
Citizenship Status:	German

B. EDUCATION
Time Period	Occupation
July 2016 - now	Senior Scientist at the Helmholtz Zentrum München für Gesundheit und Umwelt (HMGU), member of the group of Prof. Daniel Krappmann in the Department of Cellular Signal Transduction at the Institute of Molecular Toxicology and Pharmacology. Development of genetically modified mous models for the analysis of the regulation of signaling transduction pathways from antigen receptors of lymphocytes to the activation of the transcription factor NFkB.
January 2013 - June 2016	Scientific Head of the Cell Sorting Facility and Research Fellow for the German Cancer Research Center (DKFZ) Heidelberg at the DKTK partner site Munich (Klinikum rechts der Isar) Supporting immunological research of parter groups within the DKTK (German Consortium for Tranlational Cancer Research) in Munich including cell sorting and the generation and immunological characterization of new genetically modified mouse models.
January 2010 - December 2012	Team Leader within the group of Dr. Jürgen Ruland at the Helmholtz Zentrum München für Gesundheit und Umwelt (HMGU), Laboratory for Cell Signaling in the Immune System
March 2004 - December 2009	Postdoc in the group of Dr. Jürgen Ruland at the 3. Medical Department of the Klinikum rechts der Isar, Technical University of Munich, Investigation of genes involved in lymphomagenesis
January 2000 - February 2004	Ph.D. Student at the Max-Planck-Institute for Biochemistry in Martinsried in the Independent Junior Research Group for Apoptosis Research, Group Dr. Stefan Grimm Ph.D., finished with the Ph.D. degree (Dr. rer. nat.)
March 1998 - December 1999	Research Assistant at the Department of Pathology, University of Iowa, Iowa City (USA) Research Group Prof. Michael B. Cohen M.D.; Studies in Receptor-mediated Apoptosis in Prostatic Carcinoma Cell Lines.
July 1997 - February 1998	Research Assistant at the Charité, Medical School Berlin, Institute of Medical Genetics, Director Prof. Regine Witkowski, Department of Molecular Genetics, Group Dr. habil. Peter Nuernberg; .
May 1996 - June 1997	Community Service at the Charité Medical School Berlin, Institute of Medical Genetics, Department of Molecular Genetics.
May 1995 - Spring 1996	Research project (Diplomarbeit) for the "Diplom Chemiker" degree at the Technical University Berlin, Institute for Biochemistry and Molecular Biology, research group Dr. Ullrich Keller.
January - May 1995	Final examinations for Diploma degree at the Technical University Berlin, department of chemistry.
July - December 1994	Internship in the microbiological quality control laboratory of the pharmaceutical company "Gödecke AG Berlin": involved in routine work and special task: validation of microbiological quality control procedures.
Oct. 1990 - July 1994	Study of Chemistry at the Technical University Berlin.
Aug. 1983 - June 1990	Catholic Gymnasium Salvator, Berlin: Abitur (graduation).

C. Publications Ferch U, Kloo B, Gewies A, Pfänder V, Düwel M, Peschel C, Krappmann D, Ruland J J Exp Med. 2009 Oct 26;206(11):2313-20 Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. Hömig-Hölzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Müller W, Quintanilla-Martinez L, Gewies A, Ruland J, Rajewsky K, Zimber-Strobl U. J Exp Med. 2008 Jun 9;205(6):1317-29 Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. Ferch U, zum Büschenfelde CM, Gewies A, Wegener E, Rauser S, Peschel C, Krappmann D, Ruland J Nat Immunol. 2007 Sep;8(9):984-91 MALT1 directs B cell receptor-induced canonical nuclear factor-kappaB signaling selectively to the c-Rel subunit. Gross O, Gewies A, Finger K, Schafer M, Sparwasser T, Peschel C, Forster I, Ruland J Nature. 2006 Aug 10;442(7103):651-6 Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Gewies A, Ruland J AfCS-Nature Molecule Pages, 2005, doi:10.1038/mp.a000366.01 Bcl10 go to this article Gewies A, Grimm S Br J Cancer. 2003 Oct 20;89(8):1574-80 Cathepsin-B and cathepsin-L expression levels do not correlate with sensitivity of tumour cells to TNF-alpha-mediated apoptosis. Mund T, Gewies A, Schoenfeld N, Bauer MK, Grimm S FASEB J. 2003 Apr;17(6):696-8 Spike, a novel BH3-only protein, regulates apoptosis at the endoplasmic reticulum. Gewies A, Grimm S Cancer Res. 2003 Feb 1;63(3):682-8 UBP41 is a proapoptotic ubiquitin-specific protease. Gewies A, Rokhlin OW, Cohen MB Lab Invest. 2000 May;80(5):671-6 Ceramide induces cell death in the human prostatic carcinoma cell lines PC3 and DU145 but does not seem to be involved in Fas-mediated apoptosis. Gewies A, Rokhlin OW, Cohen MB Cancer Res. 2000 Apr 15;60(8):2163-8 Cytochrome c is involved in Fas-mediated apoptosis of prostatic carcinoma cell lines. Rokhlin OW, Gudkov AV, Kwek S, Glover RA, Gewies AS, Cohen MB Oncogene. 2000 Apr 6;19(15):1959-68 p53 is involved in tumor necrosis factor-alpha-induced apoptosis in the human prostatic carcinoma cell line LNCaP. Toliat MR, Erdogan F, Gewies A, Fahsold R, Buske A, Tinschert S, Nurnberg P. Electrophoresis. 2000 Feb;21(3):541-4 Analysis of the NF1 gene by temperature gradient gel electrophoresis reveals a high incidence of mutations in exon 4b. Fahsold R, Hoffmeyer S, Mischung C, Gille C, Ehlers C, Kucukceylan N, Abdel-Nour M, Gewies A, Peters H, Kaufmann D, Buske A, Tinschert S, Nurnberg P Am J Hum Genet. 2000 Mar;66(3):790-818 Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Buske A, Gewies A, Lehmann R, Ruther K, Algermissen B, Nurnberg P, Tinschert S Am J Med Genet. 1999 Oct 8;86(4):328-30 Recurrent NF1 gene mutation in a patient with oligosymptomatic neurofibromatosis type 1 (NF1). Tinschert S, Gerl H, Gewies A, Jung HP, Nurnberg P Am J Med Genet. 1999 Mar 12;83(2):100-8 McCune-Albright syndrome: clinical and molecular evidence of mosaicism in an unusual giant patient. Klose A, Ahmadian MR, Schuelke M, Scheffzek K, Hoffmeyer S, Gewies A, Schmitz F, Kaufmann D, Peters H, Wittinghofer A, Nurnberg P Hum Mol Genet. 1998 Aug;7(8):1261-8 Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. Klose A, Robinson N, Gewies A, Kluwe L, Kaufmann D, Buske A, Tinschert S, Peters H Hum Genet. 1998 Mar;102(3):367-71 Two novel mutations in exons 19a and 20 and a BsaBI polymorphism in a newly characterized intron of the neurofibromatosis type 1 gene. Pahl A, Gewies A, Keller U. Microbiology. 1997 Jan;143 ( Pt 1):117-26 ScCypB is a novel second cytosolic cyclophilin from Streptomyces chrysomallus which is phylogenetically distant from ScCypA.